Share-based compensation expense is recognized in cost of services, product and technology expense, and selling, general, and administrative expense, in the accompanying condensed consolidated statements of operations and comprehensive income (loss) as follows (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2026		2025		2026		2025
Share-based compensation expense
Cost of services	$	871	$	556	$	1,496	$	1,088
Product and technology expense		1,643		1,806		3,052		2,609
Selling, general, and administrative expense		2,726		3,380		5,122		10,012
Total share-based compensation expense	$	5,240	$	5,742	$	9,670	$	13,709

Prior to the Company’s 2021 Initial Public Offering (“IPO”), all share-based awards were issued by Fastball Holdco, L.P., the Company’s previous parent company, under individual grant agreements and the partnership agreement of such parent company (collectively, the “2020 Equity Plan”). In connection with the IPO, the Company adopted the 2021 Omnibus Incentive Plan (as amended by the First Amendment, dated as of May 10, 2023, the “2021 Equity Plan”).

In October 2024, as part of the Sterling Acquisition, unvested Sterling restricted stock, restricted stock units, and net option shares underlying in-the-money stock option awards were converted to an unvested cash award, an unvested First Advantage restricted stock award, or a First Advantage restricted stock unit (“RSU”) at the holder’s election. Converted awards are subject to the same terms and conditions (including vesting) as applied to the replaced Sterling equity award. All out-of-the-money Sterling stock options, whether vested or unvested, were canceled for no consideration.

As of June 30, 2026, the Company had approximately $55.2 million of unrecognized pre-tax non-cash compensation expense related to its equity-based compensation plans. This amount includes approximately $30.8 million related to RSUs, $24.1 million related to stock options, and $0.3 million related to restricted stock. The Company expects to recognize this expense over a weighted average period of 1.9 years.

Awards issued under the 2020 Equity Plan consist of options and profit interests. No awards have been issued under the plan since the Company’s IPO.

A summary of the stock option activity for the six months ended June 30, 2026 is as follows:


		Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value
December 31, 2025	Grants outstanding		1,275,393		$	5.15
	Grants exercised		(60,601	)	$	5.11
June 30, 2026	Grants outstanding		1,214,792		$	5.15	3.7 Years	$15.7 million
June 30, 2026	Grants vested		1,099,547		$	5.14	3.6 Years	$14.2 million
June 30, 2026	Grants unvested		115,245		$	5.23

The 2021 Equity Plan is intended to provide a means through which to attract and retain key personnel and to provide a means whereby our directors, officers, employees, consultants, and advisors can acquire and maintain an equity interest in us, or be paid incentive compensation, including incentive compensation measured by reference to the value of our common stock, thereby strengthening their commitment to our welfare and aligning their interests with those of our stockholders. The 2021 Equity Plan provides for the grant of awards of stock options, stock appreciation rights, restricted shares, restricted stock units, and other equity-based or cash-based awards as determined by the Company’s Compensation Committee. The 2021 Equity Plan initially had a total of 17,525,000 shares of common stock reserved. The number of reserved shares automatically increases on the first day of each calendar year commencing on January 1, 2022 and ending on January 1, 2030, in an amount equal to the lesser of (x) 2.5% of the total number of shares of common stock outstanding on the last day of the immediately preceding calendar year and (y) a number of shares as determined by the Board of Directors. As of June 30, 2026, 22,044,326 shares were available for issuance under the 2021 Equity Plan.

A summary of the stock option activity for the six months ended June 30, 2026 is as follows:


		Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value
December 31, 2025	Grants outstanding		5,225,103		$	14.52
	Grants issued		2,867,530		$	12.19
	Grants exercised		(213,582	)	$	13.45
	Grants cancelled/forfeited		(118,856	)	$	12.55
June 30, 2026	Grants outstanding		7,760,195		$	13.72	7.5 Years	$33.9 million
June 30, 2026	Grants vested		3,648,546		$	13.97	5.6 Years	$14.9 million
June 30, 2026	Grants unvested		4,111,649		$	13.49

The fair value for stock options granted for the six months ended June 30, 2026 was estimated at the date of grant using the Black-Scholes option-pricing model with the following weighted average assumptions:


	Options
Expected stock price volatility		48.64	%
Risk-free interest rate		3.76	%
Expected term (in years)		6.25
Fair-value of the underlying unit	$	12.19

A summary of the RSU activity for the six months ended June 30, 2026 is as follows:


		Shares			Weighted Average Grant Date Fair Value
December 31, 2025	Nonvested RSUs		883,532		$	16.18
	Granted		2,004,022		$	12.26
	Vested		(217,938	)	$	15.85
	Forfeited		(46,834	)	$	12.83
June 30, 2026	Nonvested RSUs		2,622,782		$	13.27

A summary of the restricted stock activity for the six months ended June 30, 2026 is as follows:


		Shares			Weighted Average Grant Date Fair Value
December 31, 2025	Nonvested restricted stock		448,223		$	11.74
	Vested		(448,223	)	$	13.32
June 30, 2026	Nonvested restricted stock		—		$	-

A summary of the RSU activity for the six months ended June 30, 2026 is as follows:


		Shares			Weighted Average Grant Date Fair Value
December 31, 2025	Nonvested RSUs		9,525		$	18.70
	Vested		(6,705	)	$	18.70
June 30, 2026	Nonvested RSUs		2,820		$	18.70

A summary of the restricted stock activity for the six months ended June 30, 2026 is as follows:


		Shares			Weighted Average Grant Date Fair Value
December 31, 2025	Nonvested restricted stock		180,766		$	18.70
	Vested		(131,728	)	$	18.70
	Forfeited		(18,718	)	$	18.70
June 30, 2026	Nonvested restricted stock		30,320		$	18.70

The Company’s ESPP allows eligible employees to voluntarily make after-tax contributions of up to 15% of such employee’s cash compensation to acquire Company stock during designated offering periods. Each offering period consists of one six-month purchase period. During the holding period, ESPP purchased shares are not eligible for sale or broker transfer. The Company recorded an associated expense of approximately $0.2 million and $0.1 million for the three months ended June 30, 2026 and 2025, respectively. The Company recorded an associated expense of approximately $0.5 million and $0.3 million for the six months ended June 30, 2026 and 2025, respectively.